Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-09-2006 | Original article

Comparison of ¹⁸F-FDG-PET and standard procedures for the pretreatment staging of children and adolescents with Hodgkin’s disease

Authors: Edita Kabickova, David Sumerauer, Eliska Cumlivska, Eva Drahokoupilova, Michaela Nekolna, Marketa Chanova, Marie Hladikova, Roman Kodet, Otakar Belohlavek

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 9/2006

Abstract

Purpose

The aim of this study was to perform a prospective, blinded comparison of¹⁸F-fluorodeoxyglucose positron emission tomography (FDG-PET) and conventional staging methods (CSMs) for initial staging of children and adolescents with Hodgkin’s disease (HD).

Methods

Over a period of 4 years, 55 children and adolescents with HD (mean age 15.5 years, range 3.9–18.9 years) were prospectively recruited into the study. They underwent 61 FDG-PET studies using a dedicated whole-body PET scanner as a part of their initial staging work-up. PET findings were correlated with the results of CSMs, including computed tomography (CT), ultrasound, bone scanning and bone marrow examination. Discordant findings were resolved by magnetic resonance imaging or clinical follow-up (range 2–47 months).

Results

PET correctly changed the staging in 15% of patients (seven upstagings, two downstagings). Only two out of 61 patients (3%) were not accurately staged by PET; in these children, PET missed small lymphoma nodules detected on lung CT. The sensitivity of PET and CSMs for pretreatment staging was 96.5% and 87.5%, respectively; specificity was 100% and 60%, and accuracy, 96.7% and 85.2%, respectively. Upon combination of FDG-PET and lung CT, the diagnostic accuracy reached 100% in our series.

Conclusion

Our study showed that whole-body FDG-PET is an efficient and useful method for the initial staging of children with HD. FDG-PET in combination with lung CT should be recommended as a screening method prior to other conventional imaging modalities to plan a rational staging protocol. Large multicentre prospective studies are necessary to verify this conclusion.

Schellong G, Potter R, Bramswig J, Wagner W, Prott FJ, Dorffel W, et al. High cure rates and reduced long-term toxicity in pediatric Hodgkin’s disease: The experience of the German-Austrian multicentre trial DAL-HD-90. The German-Austrian Pediatric Hodgkin’s Disease Study Group. J Clin Oncol 1999;17:3736–3744PubMed

Bathia S, Robison LL, Oberlin O, Greenberg M, Bunin G, Fossati-Bellani F, et al. Breast cancer and other second neoplasms after childhood Hodgkin’s disease. N Engl J Med 1996;334:745–751CrossRefPubMed

Schellong G. The balance between cure and late effects in childhood Hodgkin’s lymphoma: the experience of the German-Austrian Study Group since 1978. German-Austrian Pediatric Hodgkin’s Disease Study Group. Ann Oncol 1996;7(Suppl.4):67–72PubMed

Donaldson SS, Hudson MM, Lamborn KR, Link MP, Kun L, Billett AL, et al. VAMP and low-dose involved field radiation for children and adolescents with favorable, early stage Hodgkin’s disease: results of a prospective trial. J Clin Oncol 2002;20:3081–3087CrossRefPubMed

Hudson MM, Krasin M, Link MP, Donaldson SS, Billups C, Merchant TE, et al. Risk-adapted, combined-modality therapy with VAMP/COP and response-based, involved-field radiation for unfavorable pediatric Hodgkin’s disease. J Clin Oncol 2004;22:4541–4550CrossRefPubMed

Lieskovsky YE, Donaldson SS, Torres MA, Wong RM, Amylon MD, Link MP, et al. High-dose therapy and autologous hematopoietic stem-cell transplantation for recurrent or refractory pediatric Hodgkin’s disease: results and prognostic indices. J Clin Oncol 2004;22:4532–4540CrossRefPubMed

Weihrauch MR, Re D, Bischoff S, Dietlein M, Scheidhauer K, Krug B, et al. Whole-body positron emission tomography using¹⁸F-fluorodeoxyglucose for initial staging of patients with Hodgkin’s disease. Ann Hematol 2002;81:20–25CrossRefPubMed

Munker R, Stengel A, Stabler A, Hiller E, Brehm G. Diagnostic accuracy of ultrasound and computed tomography in the staging of Hodgkin’s disease. Verification by laparotomy in 100 cases. Cancer 1995;76:1460–1466PubMedCrossRef

Carr R, Barrington SF, Madan B, O’Doherty MJ, Saunders CA, van der Walt J, et al. Detection of lymphoma in bone marrow by whole-body positron emission tomography. Blood 1998;91:3340–3346PubMed

10.

Reske SN, Kotzerke J. FDG-PET for clinical use. Results of the 3rd German Interdisciplinary Consensus Conference, “Onco-PET”, 21 July and 19 September 2000. Eur J Nucl Med 2001;28:1707–1723CrossRefPubMed

11.

Lister TA, Crowther D, Sutcliffe SB, Glatstein E, Canellos GP, Young RC, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: Cotswolds meeting. J Clin Oncol 1989;7:1630–1636PubMed

12.

Stumpe KD, Urbinelli M, Steinert HC, Glanzmann C, Buck A, von Schulthess GK. Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography. Eur J Nucl Med 1998;25:721–728CrossRefPubMed

13.

Buchmann I, Reinhardt M, Elsner K, Bunjes d, Altehoefer C, Finke J, et al. 2-(Fluorine-18)fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial. Cancer 2001;91:889–899CrossRefPubMed

14.

Bangerter M, Moog F, Buchmann I, Kotzerke J, Griesshammer M, Hafner M, et al. Whole-body 2-[¹⁸F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin’s disease. Ann Oncol 1998;9:1117–1122CrossRefPubMed

15.

Wiedmann E, Baican B, Hertel A, Baum RP, Chow KU, Knupp B, et al. Positron emission tomography (PET) for staging and evaluation of response to treatment in patients with Hodgkin’s disease. Leuk Lymphoma 1999;34:545–551PubMed

16.

Partridge S, Timothy A, O’Doherty MJ, Hain SF, Rankin S, Mikhaeel G. 2-Fluorine-18-fluoro-2-deoxy-D-glucose positron emission tomography in the pretreatment staging of Hodgkin’s disease: influence on patient management in a single institution. Ann Oncol 2000;11:1273–1279CrossRefPubMed

17.

Hueltenschmidt B, Sautter-Bihl ML, Lang O, Maul FD, Fischer J, Mergenthaler HG, et al. Whole body positron emission tomography in the treatment of Hodgkin disease. Cancer 2001;91:302–310CrossRefPubMed

18.

Jerusalem G, Beguin Y, Fassotte MF, Najjar F, Paulus P, Rigo P, et al. Whole-body positron emission tomography using¹⁸F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin’s disease. Haematologica 2001;86:266–273PubMed

19.

Montravers F, McNamara D, Landman-Parker J, Grahek D, Kerrou K, Younsi N, et al. [¹⁸F]FDG in childhood lymphoma: clinical utility and impact on management. Eur J Nucl Med Mol Imaging 2002;29:1155–1165CrossRefPubMed

20.

Depas G, De Barsy C, Jerusalem G, Hoyoux C, Dresse MF, Fassotte MF, et al.¹⁸F-FDG PET in children with lymphomas. Eur J Nucl Med Mol Imaging 2005;32:31–38CrossRefPubMed

21.

Wickmann L, Lüders H, Dörffel W. 18-FDG-PET-findings in children and adolescents with Hodgkin’s disease: retrospective evaluation of the correlation to other imaging procedures in initial staging and to the predictive value of follow up examinations. Klin Padiatr 2003;215:146–150CrossRefPubMed

22.

Hermann S, Wormanns D, Pixberg M, Hunold A, Heindel W, Jurgens H, et al. Staging in childhood lymphoma: differences between FDG-PET and CT. Nuklearmedizin 2005;44:1–7PubMed

23.

Moog F, Kotzerke J, Reske SN. FDG PET can replace bone scintigraphy in primary staging of malignant lymphoma. J Nucl Med 1999;40:1407–1413PubMed

24.

Elstrom R, Guan L, Baker G, Nakhoda K, Vergilio JA, Zhuang H, et al. Utility of FDG-PET scanning in lymphoma by WHO classification. Blood 2003;101:3875–3876CrossRefPubMed

25.

Menzel C, Döbert N, Mitrou P, Mose S, Diel M, Berner U, et al. Positron emission tomography for the staging of Hodgkin’s lymphoma—increasing the body of evidence in favor of the method. Acta Oncol 2002;41:430–436CrossRefPubMed

Title: Comparison of 18F-FDG-PET and standard procedures for the pretreatment staging of children and adolescents with Hodgkin’s disease
Authors: Edita Kabickova
David Sumerauer
Eliska Cumlivska
Eva Drahokoupilova
Michaela Nekolna
Marketa Chanova
Marie Hladikova
Roman Kodet
Otakar Belohlavek
Publication date: 01-09-2006
Publisher: Springer-Verlag
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 9/2006
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-005-0019-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Comparison of ¹⁸F-FDG-PET and standard procedures for the pretreatment staging of children and adolescents with Hodgkin’s disease

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 9/2006

PET-CT: a case-based approach. 2005. P.S. Conti, D.K. Cham (Eds). Springer, Berlin Heidelberg New York. ISBN: 0-387-20858-5, hardcover, 308 pp, 472 illustrations, 107in colour. €119.95.

Partial volume effect correction in SPECT for striatal uptake measurements in patients with neurodegenerative diseases: impact upon patient classification

Instant gratification must wait

Preclinical evaluation of novel organometallic 99mTc-folate and 99mTc-pteroate radiotracers for folate receptor-positive tumour targeting

18F-FDG PET in a 10-year-old female patient with subacute sclerosing panencephalitis

Elevation of radiolabelled thymidine uptake in RIF-1 fibrosarcoma and HT29 colon adenocarcinoma cells after treatment with thymidylate synthase inhibitors